These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 17582309)

  • 1. [Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines].
    Gamelin E; Boisdron-Celle M; Morel A
    Therapie; 2007; 62(2):99-103. PubMed ID: 17582309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
    Deenen MJ; Cats A; Mandigers CM; Soesan M; Terpstra WE; Beijnen JH; Schellens JH
    Ned Tijdschr Geneeskd; 2012; 156(48):A4934. PubMed ID: 23191966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
    Mercier C; Ciccolini J
    Clin Colorectal Cancer; 2006 Nov; 6(4):288-96. PubMed ID: 17241513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
    Ostapowicz A; Dołegowska B
    Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].
    Boisdron-Celle M; Morel A; Gamelin E
    Ann Biol Clin (Paris); 2010; 68(1):27-32. PubMed ID: 20146975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of dihydropyrimidine dehydrogenase (DPD) deficiency with severe side effects from UFT/Uzel administration].
    Kai K; Endo Y; Yoshida K; Morikawa T; Nobuhisa T; Watanabe T; Matsumoto Y; Yamada T; Doi Y; Nakashima A; Nagahiro W; Ishizuka S; Sato S; Nakashima A; Nabeyama A
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):339-41. PubMed ID: 18281779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should DPD analysis be required prior to prescribing fluoropyrimidines?
    Yen JL; McLeod HL
    Eur J Cancer; 2007 Apr; 43(6):1011-6. PubMed ID: 17350823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
    Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
    Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
    Loganayagam A; Arenas-Hernandez M; Fairbanks L; Ross P; Sanderson JD; Marinaki AM
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):403-6. PubMed ID: 19795123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
    Saif MW; Diasio R
    Clin Colorectal Cancer; 2006 Jan; 5(5):359-62. PubMed ID: 16512996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
    Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
    Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
    Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
    Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
    Caudle KE; Thorn CF; Klein TE; Swen JJ; McLeod HL; Diasio RB; Schwab M
    Clin Pharmacol Ther; 2013 Dec; 94(6):640-5. PubMed ID: 23988873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
    Diasio RB
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
    Boisdron-Celle M; Remaud G; Traore S; Poirier AL; Gamelin L; Morel A; Gamelin E
    Cancer Lett; 2007 May; 249(2):271-82. PubMed ID: 17064846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
    Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
    Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.
    Sadahiro S; Suzuki T; Maeda Y; Ishikawa K; Tanaka Y; Yasuda S; Kamijo A; Makuuchi H; Murayama C
    Chemotherapy; 2007; 53(6):442-5. PubMed ID: 17952005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [5-fluorouracil and dihydropyrimidine dehydrogenase].
    Kubota T
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
    Omura K
    Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.